Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005
Clinical features of asthma complicated with eosinophilic otitis media and the effect of treatment with the anti-IgE monoclonal antibody omalizumub Source: International Congress 2015 – Co-existing diseases and asthma Year: 2015
Omalizumab, a recombinant humanized monoclonal anti-IgE antibody, decreases the risk of serious asthma exacerbations requiring hospitalization in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Treatment of asthma above and beyond anti IgE: an update for the clinician The use of biologicals in asthma treatment Source: International Congress 2018 – Difficult paediatric lung disease Year: 2018
Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases Source: Eur Respir Rev 2008; 17: 1-9 Year: 2008
Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Determining early response to anti-IL5/IL5R monoclonal antibodies in severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Age is a predictor of efficacy of monoclonal antibodies in allergic severe asthma Source: International Congress 2019 – COPD, asthma and rhinitis: from cellular mechanisms to patients’ clinical responses Year: 2019
The rationale for treating allergic asthma with anti-IgE Source: Eur Respir Rev 2007; 16: 61-66 Year: 2007
Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Change of T2-markers in patients with severe uncontrolled asthma treated by monoclonal antibodies: 1 yr follow up Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases Year: 2021
Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018
Evaluation of bronchial hyperreactivity and other functional parameters in severe asthma patients treated with anti-interleukin-5 monoclonal antibody (IL5) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Long-term treatment with monoclonal antibodies anti-IgE in severe asthma: Follow-up of ten patients Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011
The Dutch hypothesis, implications for treatment of chronic obstructive pulmonary disease and asthma in a biomarker, monoclonal antibody world. Experience with IgE and omalizumab in a small pulmonary practice Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002
Effect of humanized monoclonal anti-IgE antibody, omalizumab, on allergen challenge-induced nasal response in subjects with allergic rhinitis and allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
Antinuclear antibodies and severe evolution of asthma Source: Annual Congress 2007 - Towards controlling severe asthma Year: 2007
Tolerability assessment of a recombinant humanized monoclonal anti-IgE antibody (omalizumab) as a treatment for seasonal allergic rhinitis Source: Eur Respir J 2002; 20: Suppl. 38, 116s Year: 2002
Monoclonal antibody treatments for paediatric severe asthma–outcomes, attitudes and adherence Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021